|
Synonyms: ALN-81890 | BRII-835 | VIR-2218
Compound class:
Nucleic acid
Comment: Elebsiran (VIR-2218) is a N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) that is designed to target hepatitis B virus (HBV) RNA as a mechanism to combat chronic HBV infection [2]. The nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone.
|
| No information available. |
Summary of Clinical Use ![]() |
| Elebsiran (VIR-2218) was progressed as a clinical candidate for potential to treat (and eliminate) Hepatitis B viral infection [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06903338 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Phase 3 Interventional | Vir Biotechnology, Inc. | ||
| NCT07128550 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | Phase 3 Interventional | Vir Biotechnology, Inc. | ||
| NCT03672188 | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B | Phase 1/Phase 2 Interventional | Vir Biotechnology, Inc. | 2-3 | |